BIIB · Biogen Inc. · Earnings Call Transcripts & Audio
$225.88
-1.19 (-0.52%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$33.52B
Shares
147.64M
Volume · Sep 30
1.55M
Avg daily vol (3M)
1.08M
Biogen Inc. Earnings Call Transcripts
Quarterly earnings calls for Biogen Inc. (BIIB), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼6.9%
$2.54B
$550.40M
'22 Q4
23-02-15
▼2.7%
$2.46B
$387.90M
'23 Q1
23-04-25
▼5.1%
$2.46B
$591.60M
'23 Q2
23-07-25
▲0.9%
$2.53B
−$68.10M
'23 Q3
23-11-08
▼6.2%
$2.39B
$249.70M
'23 Q4
24-02-13
▼7%
$2.29B
$393.40M
'24 Q1
24-04-24
▲0.4%
$2.46B
$583.60M
'24 Q2
24-08-01
▼2.5%
$2.47B
$388.50M
'24 Q3
24-10-30
▲2.9%
$2.45B
$266.70M
'24 Q4
25-02-12
▲6.1%
$2.43B
$240.50M
'25 Q1
25-05-01
▲7.3%
$2.65B
$634.80M
'25 Q2
25-07-31
▲2.8%
$2.53B
$466.50M
'25 Q3
25-10-30
▼7.1%
$2.28B
−$48.90M
'25 Q4
26-02-06
LATEST
▲1.9%
$2.48B
$319.50M
'26 Q1
26-04-29
Earnings call
FY26 · Q3
2026-10-28
Biogen Inc. (BIIB) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
Biogen Inc. (BIIB) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Biogen Inc. (BIIB) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-29
Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript
Confident tone
Late-stage registrational pipeline
BTK inhibitor (BIP-91) and competitive MS market
Appellu acquisition integration
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-07-14
Biogen Inc. (BIIB) July 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-07-12
Biogen Inc. (BIIB) July 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-07-07
Biogen Inc. (BIIB) July 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-29
Biogen Inc. (BIIB) Q1 2026 Earnings Call Transcript
Confident tone
Leqembi franchise and care pathway
Pellas/Pelagos acquisition
Growth product momentum
Revenue
$2.48B
▲ 1.9% YoY Diluted EPS
$2.15
▲ 31.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-06
Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript
Confident tone
Leqembi / Alzheimer's franchise
Pipeline and R&D progress
Newer product launches (Skyclaris, XERZUVEY, SPINRAZA HD)
Revenue
$2.28B*
▼ 7.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript
Confident tone
Launch product momentum
Late-stage pipeline and readouts
Tau / BIIB080 readout and external data read-throughs
Revenue
$2.53B
▲ 2.8% YoY Diluted EPS
$3.17
▲ 19.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript
Confident tone
LEQEMBI / Alzheimer's franchise
Pipeline progress and milestones
Eisai partnership / Europe arbitration
Revenue
$2.65B
▲ 7.3% YoY Diluted EPS
$4.33
▲ 8.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript
Positive tone
Pipeline and external innovation
LEQEMBI launch and growth
Alzheimer's prevention trials
Revenue
$2.43B
▲ 6.1% YoY Diluted EPS
$1.64
▼ 39.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-12
Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript
Positive tone
LEQEMBI growth and Alzheimer's franchise
New product launches offsetting MS decline
Pipeline reprioritization and future readouts
Revenue
$2.45B*
▲ 2.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Biogen Inc. (BIIB) Q3 2024 Earnings Call Transcript
Positive tone
ZURZUVAE launch
SKYCLARYS global expansion
LEQEMBI launch
Revenue
$2.47B
▼ 2.5% YoY Diluted EPS
$2.66
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Biogen Inc. (BIIB) Q2 2024 Earnings Call Transcript
Confident tone
LEQEMBI and Alzheimer's franchise
Business development and M&A (HI-Bio)
New product launches (SKYCLARYS, ZURZUVAE, Reata)
Revenue
$2.46B
▲ 0.4% YoY Diluted EPS
$4.00
▼ 1.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-24
Biogen Inc. (BIIB) Q1 2024 Earnings Call Transcript
Positive tone
LEQEMBI launch and Alzheimer's market
Quarterly financial performance
SKYCLARYS launch and rare disease
Revenue
$2.29B
▼ 7% YoY Diluted EPS
$2.70
▲ 1.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-13
Biogen Inc. (BIIB) Q4 2023 Earnings Call Transcript
Confident tone
LEQEMBI (Alzheimer's disease franchise)
SKYCLARYS launch and Friedreich's Ataxia
International expansion (Japan, Europe, Latin America)
Revenue
$2.39B*
▼ 6.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Biogen Inc. (BIIB) Q3 2023 Earnings Call Transcript
Revenue
$2.53B
▲ 0.9% YoY Diluted EPS
$-0.47
▼ 106% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-25
Biogen Inc. (BIIB) Q2 2023 Earnings Call Transcript
Revenue
$2.46B
▼ 5.1% YoY Diluted EPS
$4.07
▼ 43.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-25
Biogen Inc. (BIIB) Q1 2023 Earnings Call Transcript
Revenue
$2.46B
▼ 2.7% YoY Diluted EPS
$2.67
▲ 29.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-15
Biogen Inc. (BIIB) Q4 2022 Earnings Call Transcript
Revenue
$2.54B*
▼ 6.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-25
Biogen Inc. (BIIB) Q3 2022 Earnings Call Transcript
Revenue
$2.51B
▼ 9.7% YoY Diluted EPS
$7.84
▲ 253.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-20
Biogen Inc. (BIIB) Q2 2022 Earnings Call Transcript
Revenue
$2.59B
▼ 6.7% YoY Diluted EPS
$7.24
▲ 142.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Biogen Inc. (BIIB) Q1 2022 Earnings Call Transcript
Revenue
$2.53B
▼ 6% YoY Diluted EPS
$2.06
▼ 23.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-03
Biogen Inc. (BIIB) Q4 2021 Earnings Call Transcript
Revenue
$2.73B*
▼ 4.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-20
Biogen Inc. (BIIB) Q3 2021 Earnings Call Transcript
Revenue
$2.78B
▼ 17.7% YoY Diluted EPS
$2.22
▼ 50.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-22
Biogen Inc. (BIIB) Q2 2021 Earnings Call Transcript
Revenue
$2.77B
▼ 24.6% YoY Diluted EPS
$2.99
▼ 68.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-22
Biogen Inc. (BIIB) Q1 2021 Earnings Call Transcript
Revenue
$2.69B
▼ 23.8% YoY Diluted EPS
$2.69
▼ 66.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-03
Biogen Inc. (BIIB) Q4 2020 Earnings Call Transcript
Revenue
$2.85B
▼ 22.3% YoY Diluted EPS
$2.32
▼ 71.3% YoY Gross margin
82.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-21
Biogen Inc. (BIIB) Q3 2020 Earnings Call Transcript
Revenue
$3.38B
▼ 6.2% YoY Diluted EPS
$4.46
▼ 46.8% YoY Gross margin
86.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-22
Biogen Inc. (BIIB) Q2 2020 Earnings Call Transcript
Revenue
$3.68B
▲ 1.8% YoY Diluted EPS
$9.59
▲ 22.2% YoY Gross margin
88.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-22
Biogen Inc. (BIIB) Q1 2020 Earnings Call Transcript
Revenue
$3.53B
▲ 1.3% YoY Diluted EPS
$8.08
▲ 13% YoY Gross margin
87.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-30
Biogen Inc. (BIIB) Q4 2019 Earnings Call
Revenue
$3.67B
▲ 4.1% YoY Diluted EPS
$8.08
▲ 70.8% YoY Gross margin
87.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–33 of 33 earnings calls
Key facts
CIK
875045
CUSIP
09062X103
13F (30d)
23 filings
18 filers
Visit website
Investor relations